Brexpiprazole
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation Associated With Alzheimer's Dementia
Conditions
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
Trial Timeline
May 16, 2018 → Jun 1, 2022
NCT ID
NCT03548584About Brexpiprazole
Brexpiprazole is a phase 3 stage product being developed by Lundbeck for Agitation Associated With Alzheimer's Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT03548584. Target conditions include Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05504486 | Approved | Withdrawn |
| NCT04830215 | Approved | Completed |
| NCT04258839 | Phase 3 | Completed |
| NCT03548584 | Phase 3 | Completed |
| NCT03287869 | Phase 3 | Completed |
| NCT03292848 | Phase 1 | Completed |
| NCT03238326 | Phase 3 | Completed |
| NCT01944969 | Phase 3 | Terminated |
| NCT01942785 | Phase 3 | Completed |
| NCT01942733 | Phase 3 | Completed |
| NCT01810783 | Phase 3 | Completed |
Competing Products
20 competing products in Agitation Associated With Alzheimer's Dementia